A link between histone deacetylases (HDACs) and intestinal inflammation has been established. HDAC inhibitors that target gut-selective inflammatory pathways represent a potential new therapeutic strategy in patients with refractory inflammatory bowel diseases (IBD).
Felice, C., Lewis, A., Armuzzi, A., Lindsay, J., Silver, A., Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases, <<ALIMENTARY PHARMACOLOGY & THERAPEUTICS>>, 2015; 41 (1): 26-38. [doi:10.1111/apt.13008] [http://hdl.handle.net/10807/64558]
Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases
Armuzzi, Alessandro;
2014
Abstract
A link between histone deacetylases (HDACs) and intestinal inflammation has been established. HDAC inhibitors that target gut-selective inflammatory pathways represent a potential new therapeutic strategy in patients with refractory inflammatory bowel diseases (IBD).
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
